Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28726405 | 0.82 | XDH (0.70) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B | |
| SCHEMBL7110910 | 0.81 | XDH (0.69) | XDHADORA3SMN1; SMN2TMIGD3HTR2C | |
| SCHEMBL21595204 | 0.81 | XDH (0.69) | XDHADORA3ADORA2ASMN1; SMN2TMIGD3 | |
| SCHEMBL11876697 | 0.80 | XDH (0.67) | XDHADORA3ADORA2ABRAF | |
| SCHEMBL20565 | 0.80 | XDH (0.67) | XDHADORA3ADORA2ABRAF | |
| SCHEMBL30523428 | 0.80 | XDH (0.67) | XDHADORA3ADORA2ABRAF | |
| SCHEMBL5694220 | 0.79 | XDH (0.65) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B | |
| SCHEMBL16146631 | 0.79 | XDH (0.65) | XDHADORA3SMN1; SMN2TMIGD3HTR2C | |
| SCHEMBL29444888 | 0.79 | XDH (0.64) | XDHADORA3SMN1; SMN2TMIGD3HTR2C | |
| SCHEMBL28252065 | 0.79 | XDH (0.64) | XDHADORA3SMN1; SMN2TMIGD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516637-B1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | PLASMIA BIOTECH S L (ES) | 2016-04-20 | — | — | EP | claimed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-102770532-A | Thermostable biocatalyst conjugates for nucleoside synthesis | PLASMIA BIOTECH S L | 2012-11-07 | — | — | CN | claimed |
| EP-2516637-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | Plasmia Biotech, S.L. (ES) | 2012-10-31 | — | — | EP | claimed |
| US-20120264175-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | BRILL ENGINES, S.L. (ES) | 2012-10-18 | — | — | US | claimed |
| WO-2011076894-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| EP-2338985-A1 | Thermostable biocatalyst combination for nucleoside synthesis | Institut Univ. de Ciència i Tecnologia, s.a. (ES) | 2011-06-29 | — | — | EP | claimed |
| US-20080089957-A1 | Monocotyledon plant indications extract compositions, method of preparation and pharmaceutical compositions containing them | ACADEMIA SINICA (TW) | 2008-04-17 | — | — | US | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-108703970-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2018-10-26 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| EP-2516637-B1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | PLASMIA BIOTECH S L (ES) | 2016-04-20 | — | — | EP | disclosed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| EP-2134683-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2057159-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-05-13 | — | — | EP | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080089957-A1 | Monocotyledon plant indications extract compositions, method of preparation and pharmaceutical compositions containing them | ACADEMIA SINICA (TW) | 2008-04-17 | — | — | US | disclosed |
| WO-2008017161-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | XDH 253/4885ADORA3 1280/4885ADORA2A 511/4885 |
| US-20080089957-A1 | Monocotyledon plant indications extract compositions, method of preparation and pharmaceutical compositions containing them | OAT, TPMT, NUDT1 | XDH 5/4885ADORA3 478/4885ADORA2A 630/4885 |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | XDH 1667/4885ADORA3 3583/4885ADORA2A 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.